NCT01298063View on ClinicalTrials.gov

Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

January 31, 2012

Conditions
Liver DiseasesHealthy
Interventions
DRUG

Afatinib

1 tablet, once qd in the morning

DRUG

Afatinib

1 tablet, once qd in the morning

DRUG

Afatinib

1 tablet, once qd in the morning

Trial Locations (1)

Unknown

1200.86.1 Boehringer Ingelheim Investigational Site, Kiel

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY